| Market Cap | 96.61M | P/E | - | EPS this Y | 26.00% | Ern Qtrly Grth | - |
| Income | -85.12M | Forward P/E | -1.03 | EPS next Y | 27.50% | 50D Avg Chg | 53.00% |
| Sales | - | PEG | -0.03 | EPS past 5Y | - | 200D Avg Chg | -44.00% |
| Dividend | N/A | Price/Book | 0.61 | EPS next 5Y | 15.50% | 52W High Chg | -85.00% |
| Recommedations | 1.80 | Quick Ratio | 6.62 | Shares Outstanding | 44.36M | 52W Low Chg | 96.00% |
| Insider Own | 18.44% | ROA | -37.74% | Shares Float | 33.53M | Beta | 1.52 |
| Inst Own | 54.11% | ROE | -66.95% | Shares Shorted/Prior | 7.19M/6.99M | Price | 2.18 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,120,770 | Target Price | 21.17 |
| Oper. Margin | - | Earnings Date | Feb 22 | Volume | 647,848 | Change | -2.77% |
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
| SVB Leerink | Market Perform | Oct 21, 22 |
| Aegis Capital | Buy | Aug 8, 22 |
| SVB Leerink | Outperform | Jun 3, 22 |
| Piper Sandler | Overweight | May 18, 22 |
| HC Wainwright & Co. | Buy | Sep 7, 21 |
| Aegis Capital | Buy | Apr 15, 21 |
| JMP Securities | Market Outperform | Mar 24, 21 |
| SVB Leerink | Outperform | Oct 2, 20 |
| Piper Sandler | Overweight | Aug 26, 20 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Neermann Joerg | Director Director | Nov 23 | Buy | 1.39 | 18,000 | 25,020 | 18,000 | 11/25/22 |
| Vitt Daniel | President and CEO President and CEO | Nov 22 | Buy | 1.3499 | 8,000 | 10,799 | 376,877 | 11/23/22 |
| Whaley Glenn | Chief Financial Offi.. Chief Financial Officer | Nov 07 | Buy | 1.495 | 5,000 | 7,475 | 20,510 | 11/08/22 |
| Vitt Daniel | President and CEO President and CEO | Jun 03 | Buy | 3.0999 | 5,000 | 15,500 | 368,877 | 06/06/22 |
| Whaley Glenn | Chief Financial Offi.. Chief Financial Officer | Jun 03 | Buy | 3.045 | 3,500 | 10,658 | 12,568 | 06/06/22 |
| Muehler Andreas | Chief Medical Office.. Chief Medical Officer | May 12 | Buy | 5.10 | 3,500 | 17,850 | 297,986 | 05/16/22 |